药明康德再一次证明自己！一季度新增客户300+，CDMO分子数保持强劲增长

挖贝网04-30

前期受美国拟议法案影响的药明康德发布了2024年的第一份业绩报告，该公司表示在外部环境挑战下，第一季度达成目标，保持稳健经营态势。药明康德一季度实现营收79.82亿元，剔除新冠商业化项目同比下降1.8%，归母净利润19.42亿元，经调整non-IFRS归母净利润19.13亿元，自由现金流持续为正。在拟议法案扰动下，市场普遍认为药明康德的海外市场特别是美国市场将会有较为明显的下降，而实际其美国地区...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2431385717?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-30 10:14","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2431385717","market":"sh","top_or_hot":-1,"title":"药明康德再一次证明自己！一季度新增客户300+，CDMO分子数保持强劲增长","media":"挖贝网","content":"<div>\n<p>前期受美国拟议法案影响的药明康德发布了2024年的第一份业绩报告，该公司表示在外部环境挑战下，第一季度达成目标，保持稳健经营态势。药明康德一季度实现营收79.82亿元，剔除新冠商业化项目同比下降1.8%，归母净利润19.42亿元，经调整non-IFRS归母净利润19.13亿元，自由现金流持续为正。在拟议法案扰动下，市场普遍认为药明康德的海外市场特别是美国市场将会有较为明显的下降，而实际其美国地区...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043010152587c1af09&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>药明康德再一次证明自己！一季度新增客户300+，CDMO分子数保持强劲增长</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n药明康德再一次证明自己！一季度新增客户300+，CDMO分子数保持强劲增长\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-30 10:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043010152587c1af09&s=b><strong>挖贝网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>前期受美国拟议法案影响的药明康德发布了2024年的第一份业绩报告，该公司表示在外部环境挑战下，第一季度达成目标，保持稳健经营态势。药明康德一季度实现营收79.82亿元，剔除新冠商业化项目同比下降1.8%，归母净利润19.42亿元，经调整non-IFRS归母净利润19.13亿元，自由现金流持续为正。在拟议法案扰动下，市场普遍认为药明康德的海外市场特别是美国市场将会有较为明显的下降，而实际其美国地区...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043010152587c1af09&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02359","symbol_name":"药明康德","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043010152587c1af09&s=b","article_id":"2431385717","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043010152587c1af09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2431385717","pubTimestamp":1714443258,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"前期受美国拟议法案影响的药明康德发布了2024年的第一份业绩报告，该公司表示在外部环境挑战下，第一季度达成目标，保持稳健经营态势。药明康德一季度实现营收79.82亿元，剔除新冠商业化项目同比下降1.8%，归母净利润19.42亿元，经调整non-IFRS归母净利润19.13亿元，自由现金流持续为正。一季度药明康德新增客户依旧超过 300家，与去年超过310家相差无几。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603259":"药明康德","02359":"药明康德","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","BK0216":"研究试验","LU1997245177.USD":"安联神洲A股基金"},"translate_title":"WuXi AppTec once again proves itself! 300 new customers were added in the first quarter, and the number of CDMO molecules maintained strong growth","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1,"02359":0.9},"content_text":"前期受美国拟议法案影响的药明康德发布了2024年的第一份业绩报告，该公司表示在外部环境挑战下，第一季度达成目标，保持稳健经营态势。药明康德一季度实现营收79.82亿元，剔除新冠商业化项目同比下降1.8%，归母净利润19.42亿元，经调整non-IFRS归母净利润19.13亿元，自由现金流持续为正。在拟议法案扰动下，市场普遍认为药明康德的海外市场特别是美国市场将会有较为明显的下降，而实际其美国地区剔除新冠商业化项目收入与去年同期保持同等规模，而欧洲地区的增长更是来到低个位数。药明康德在业绩交流会上也直言，确实有客户就拟议法案事项表达了担忧，但从Q1来看整体没有明显影响，并没有看到大量客户的取消，只有极个别早期研发客户因为议案草案的扰动取消了部分服务。“公司有着庞大的客户群，不同客户会基于自身情况做出不同的考虑。大家都非常认可公司的极致服务和能力，毕竟在全球范围内要找到我们这样的高质量、高效率的服务和产能规模，又能确保技术水平、交付质量及交付时间的供应商，也不是很容易的事情。”一季度药明康德新增客户依旧超过 300家，与去年超过310家相差无几。活跃客户也维持在6000家以上。占公司营收一半以上的CDMO业务方面，CDMO分子总数创下历史新高来到3286个，一季度更是新增商业化和临床III期项目11个。同时，公司合同负债也增加至21.62亿元，环比增长超过10%。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431385717"}